DEPO-MEDRONE WITH LIDOCAINE

This brand name is authorized in Ireland, South Africa, UK.

Active ingredients

The drug DEPO-MEDRONE WITH LIDOCAINE contains a combination of these active pharmaceutical ingredients (APIs):

1	Methylprednisolone UNII X4W7ZR7023 - METHYLPREDNISOLONE
	Methylprednisolone is a synthetic glucocorticoid and a methyl derivative of prednisolone. Methylprednisolone is a potent anti-inflammatory agent with the capacity to profoundly inhibit the immune system.
	Read more about Methylprednisolone
2	Lidocaine UNII 98PI200987 - LIDOCAINE
	Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane.
	Read more about Lidocaine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DEPO-MEDRONE WITH LIDOCAINE Suspension for injection	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H02BX01	Methylprednisolone, combinations	H Systemic hormonal preparations, excl. Sex hormones and insulins → H02 Corticosteroids for systemic use → H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS → H02BX Corticosteroids for systemic use, combinations
Discover more medicines within H02BX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	161575, 185732, 28263, 28264, 28274, 28276, 374202, 374236, 381282
IE	Health Products Regulatory Authority	20214, 20255
ZA	Health Products Regulatory Authority	F/21.5.4/228